文献速递外周动脉疾病

在慢性肢体威胁性缺血患者中,人工血管移植物在股腘和腘下旁路术中的结局劣于大隐静脉移植物

Prosthetic conduits have worse outcomes compared with great saphenous vein conduits in femoropopliteal and infrapopliteal bypass in patients with chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2024-09-23

基于BEST-CLTI随机对照试验的按治疗分析,784例腹股沟下旁路术中比较人工血管、替代自体静脉、冷冻保存静脉与单段大隐静脉(SSGSV)的结局。股腘旁路中人工血管与3年主要再干预风险升高相关(风险比2.13,95%置信区间1.09-4.2,P=0.028);腘下旁路中人工血管与主要再干预、踝上截肢、死亡及主要不良肢体事件或死亡风险升高相关。SSGSV仍为首选移植物。

要点

  • 股腘旁路中人工血管与3年主要再干预风险升高相关(风险比2.13,95%置信区间1.09-4.2,P=0.028)。
  • 腘下旁路中人工血管与主要再干预(风险比4.14)、踝上截肢(风险比4.64)、死亡(风险比2.96)风险升高相关。
  • 冷冻保存静脉移植物结局较差,SSGSV仍为腹股沟下旁路首选移植物。

核心结论

  • 腹股沟下旁路术中使用人工血管与使用SSGSV相比结局较差,尤其在腘下靶血管旁路中。
  • 冷冻保存静脉移植物不常用,也表现出较差的结局。
  • SSGSV仍是腹股沟下旁路术的首选移植物。

研究设计与样本

  • 数据来自BEST-CLTI多中心、前瞻性、随机对照试验,比较腹股沟下旁路术与血管内治疗在CLTI患者中的效果。
  • 本分析为按治疗分析,比较人工血管、替代自体静脉(AAV)、冷冻保存静脉(Cryo)与SSGSV旁路术的结局。
  • 共分析784例旁路术(人工血管120例,AAV 33例,Cryo 21例,SSGSV 610例)。
  • 人工血管与SSGSV组中,股腘旁路357例(人工血管93例,GSV 264例),腘下旁路373例(人工血管27例,GSV 346例)。
  • 采用Kaplan-Meier和多变量分析检验移植物类型与主要不良肢体事件(MALE)、再干预、踝上截肢及全因死亡率的关联。

主要发现

  • 总体队列平均年龄67.1岁,女性27.4%,非白人29.9%,西班牙裔11.5%。
  • 人工血管组患者更年长(69.2岁 vs 66.7岁),慢性阻塞性肺疾病(22.5% vs 14.0%)、既往冠状动脉旁路移植术(88.9% vs 66.5%)和既往卒中(23.3% vs 14%)比例更高,西班牙裔(5.8% vs 12.6%)和糖尿病(59.2% vs 71.3%)比例更低(所有P<0.05)。
  • 股腘旁路中,人工血管与3年总体主要再干预增加相关(19.0% vs 11.5%;P=0.06),风险校正分析中风险比2.13(95%置信区间1.09-4.2;P=0.028);MALE或死亡、踝上截肢或死亡无显著差异。
  • 腘下旁路中,人工血管与3年主要再干预(25.3% vs 10.3%;P=0.005)、死亡(68.6% vs 34.8%;P<0.001)及MALE或死亡(90.0% vs 48.1%;P<0.001)增加相关。
  • 风险校正后,腘下旁路人工血管与主要再干预(风险比4.14;95%置信区间1.36-12.6;P=0.012)、踝上截肢(风险比4.64;95%置信区间1.59-13.5;P=0.005)、死亡(风险比2.96;95%置信区间1.4-6.2;P=0.004)及MALE或死亡(风险比3.59;95%置信区间1.64-7.86;P=0.001)风险升高相关。

临床怎么用

  • SSGSV仍是腹股沟下旁路术的首选移植物。
  • 使用人工血管与较差结局相关,尤其在腘下靶血管旁路中;冷冻保存静脉移植物结局也较差。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Single segment great saphenous vein (SSGSV) traditionally has been considered the gold standard conduit for infrainguinal bypass. There are data supporting similar outcomes with prosthetic femoral-popliteal bypass. Moreover, some investigators have advocated for prosthetic conduit for femoral tibial bypass when GSV is inadequate or unavailable. We sought to evaluate long-term outcomes of infrainguinal bypass based on conduit type for treating chronic limb-threatening ischemia (CLTI). METHODS: Data from the Best Endovascular vs Best Surgical Therapy of Patients with CLTI multicenter, prospective, randomized controlled trial, comparing infrainguinal bypass with endovascular therapy in patients with CLTI, were evaluated. In this as-treated analysis, we compared outcomes of infrainguinal bypass using prosthetic, alternative autogenous vein (AAV), and cryopreserved vein (Cryo) with SSGSV bypass. Kaplan-Meier and multivariable analyses were performed to examine the associations of conduit type with major adverse limb events (MALE), reinterventions, above-ankle amputations, and all-cause death rates. RESULTS: In total, 784 bypasses were analyzed (120 prosthetic, 33 AAV, 21 Cryo, AND 610 SSGSV). For prosthetic and SSGSV, the distribution was 357 femoropopliteal (93 prosthetic and 264 GSV) and 373 infrapopliteal (27 prosthetic and 346 GSV). The mean age for the overall cohort was 67.1 years; 27.4% were female, 29.9% were non-White, and 11.5% were of Hispanic ethnicity. Patients undergoing prosthetic bypass were older (69.2 years vs 66.7 years); more likely to have chronic obstructive pulmonary disease (22.5% vs 14.0%), prior coronary artery bypass grafting (88.9% vs 66.5%), and prior stroke (23.3% vs 14%); but less often were of Hispanic ethnicity (5.8% vs 12.6%) and had diabetes (59.2% vs 71.3%) (P < .05 for all). For femoropopliteal bypass, use of prosthetic conduit was associated with increased major reinterventions at 3 years overall (19.0% vs 11.5%; P = .06) and on risk-adjusted analysis (hazard ratio [HR], 2.13; 95% confidence interval [CI], 1.09-4.2; P = .028). No significant differences in MALE or death, above-ankle amputation, or death were observed. Outcomes were similar for bypasses to above-knee popliteal targets and below-knee popliteal targets. For infrapopliteal bypass, the use of a prosthetic conduit was associated with increased major reintervention (25.3% vs 10.3%; P = .005), death (68.6% vs 34.8%; P < .001), and MALE or death (90.0% vs 48.1%; P < .001) at 3 years. After risk adjustment, infrapopliteal bypass with prosthetic conduit was associated with higher major reintervention (HR, 4.14; 95% CI, 1.36-12.6; P = .012), above-ankle amputation (HR, 4.64; 95% CI, 1.59-13.5; P = .005), death (HR, 2.96; 95% CI, 1.4-6.2; P = .004), and MALE or death (HR, 3.59; 95% CI, 1.64-7.86; P = .001) compared with bypass with SSGSV. Overall, AAV had similar outcomes at 3 years as SSGSV; however, Cryo had significantly higher above-ankle amputation (50.0% vs 12.8%) (HR, 4.2; 95% CI, 1.68-10.5; P = .002), major reintervention (41.9% vs 10.7%) (HR, 3.12; 95% CI, 1.18-8.22; P = .02), and MALE/death (88.8% vs 37.8%) (HR, 2.96; 95% CI, 1.43-6.14; P = .004). CONCLUSIONS: The use of a prosthetic conduit in infrainguinal bypass is associated with inferior outcomes compared with bypass using SSGSV, particularly for bypass to infrapopliteal targets. Cryo grafts were infrequent and also demonstrated inferior outcomes. SSGSV remains the preferred conduit of choice for infrainguinal bypass.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Farber A, Menard MT, Conte MS, et al. Prosthetic conduits have worse outcomes compared with great saphenous vein conduits in femoropopliteal and infrapopliteal bypass in patients with chronic limb-threatening ischemia. J Vasc Surg. 2024. PMID: 39321895. doi:10.1016/j.jvs.2024.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。